University of Lincoln   Report issue

Academic/Hospital Phase 3
Founded: Lincoln United Kingdom (1861)

Organization Overview

First Clinical Trial
2020
NCT03915366
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

University of Lincoln

Active Ingredients

Drugs in Phase 3 Trials (1)

valganciclovir (Valcyte) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cytomegalovirus Infections (Phase 3)

Pneumonia (Phase 3)

Tuberculosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1